EQS.PA up 13.89% to €38.95 pre-market Mar 31, 2026: momentum may extend

EQS.PA stock is trading higher in the pre-market on 31 Mar 2026 after a 13.89% leap to €38.95, making Equasens (EQS.PA) one of the top gainers on EURONEXT in Europe this morning. Volume is elevated at 27,114 shares versus an average of 10,645, suggesting stronger-than-normal demand. Traders are reacting to the company’s latest results and positive technical signals, while analysts point to steady cash flow and a PE of 16.30 as supportive fundamentals for further upside.

EQS.PA stock: pre-market price action and drivers

Equasens (EQS.PA) opened pre-market at €35.00 and hit a session high of €39.45, closing the immediate move at €38.95 on 31 Mar 2026. The stock’s one-day change is +13.89% and its relative volume is 2.55x, indicating meaningful buying pressure. Market sources and live tickers on investing.com show increased attention to the healthcare software specialist after its earnings release and renewed client contract updates source.

EQS.PA stock fundamentals: valuation and balance-sheet checks

Equasens reports an EPS of €2.39 and a trailing PE around 16.30, with market capitalization at €585,473,030.00. Key ratios show price-to-sales 2.60, price-to-book 2.55, and free cash flow yield about 8.69%, supporting a valuation that looks reasonable versus growth expectations. The company carries low leverage with debt-to-equity near 0.21 and cash per share €5.44, which cushions the business amid slower recent revenue growth.

EQS.PA stock: technical setup and trading signals

Technical indicators show short-term momentum: RSI is 66.24 and the stock cleared the 50-day average (€37.59) toward the 200-day average (€43.05). On-chain session metrics record an ATR of €1.31 and a CCI of 208.33, suggesting the move has strength but may be overbought intraday. Traders should note the day low €34.05 as initial support and €39.45 as near-term resistance for this pre-market leg.

Meyka AI rates and EQS.PA stock forecast

Meyka AI rates EQS.PA with a score of 76.15 out of 100 (Grade: B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a quarterly target of €55.15, implying an upside of 41.60% versus the current €38.95. Forecasts are model-based projections and not guarantees.

EQS.PA stock: catalysts and risks in the healthcare sector

Primary catalysts include recurring software contract renewals, cross-selling of analytics tools, and steady dividend policy (€1.25 per share). The healthcare software sector in Europe has lagged broader tech, but offers defensive demand; sector metrics show higher average PE, making Equasens’ PE 16.30 comparatively conservative. Key risks are slower revenue growth (recent FY revenue growth -1.36%) and a long receivables cycle (DSO ~100.88 days) that can pressure working capital.

EQS.PA stock: trading considerations and price targets

For traders, the immediate plan is to monitor post-open liquidity and hold thresholds: a conservative stop under €34.05 (session low) and targets at €43.05 (200-day average) and €55.15 (Meyka quarterly model). Given average daily volume 10,645 versus current 27,114, scale-in sizes carefully. Dividend yield near 3.21% and strong interest coverage (43.63x) make the stock attractive for income-minded investors who accept modest growth risk.

Final Thoughts

EQS.PA stock is a clear pre-market top gainer on 31 Mar 2026 after jumping 13.89% to €38.95 on higher volume. Fundamentals support the move: EPS €2.39, PE 16.30, free cash flow yield 8.69%, low leverage and a €1.25 dividend per share. Meyka AI’s forecast model projects a quarterly target of €55.15, which implies a 41.60% upside from current levels, while the yearly model sits closer to €30.81, reflecting model uncertainty and different horizon assumptions. Traders should watch intraday support at €34.05 and resistance near €39.45 and €43.05. Remember that forecasts are model-based projections and not guarantees; use risk management and align position size with liquidity and holding horizon. Meyka AI’s data-driven grade and price path help frame the opportunity and risk, but investors should confirm with company filings and live market data before acting.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.